SynthesisBritish journal of cancer1998
Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group.
Synthesis in British journal of cancer, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 241 citations in OpenAlex.
- Chemotherapy for advanced ovarian cancer. Advanced Ovarian Cancer Trialists Group.The Cochrane database of systematic reviews · 2000Pooled it
- Adjuvant intensity modulated whole-abdominal radiation therapy for high-risk patients with ovarian cancer FIGO stage III: final results of a prospective phase 2 study.Radiation oncology (London, England) · 2019Trial
- Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study.Gynecologic oncology · 2018Trial
- Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer.British journal of cancer · 2001Trial
- Long-Term Survival in High-Grade Serous Ovarian Cancer Compared With the General US Population: A 30-Year Landmark Analysis.JCO oncology advances · 2026Article
- Cancer of the ovary, fallopian tube, and peritoneum: 2025 update.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025Review
- Extensive Peritonectomy is an Independent Risk Factor for Cisplatin HIPEC-Induced Acute Kidney Injury.Annals of surgical oncology · 2023Article
- Extracellular vesicles in ovarian cancer chemoresistance, metastasis, and immune evasion.Cell death & disease · 2022Review
- Assessing frequency and clinical outcomes of BRCA mutated ovarian cancer in Saudi women.BMC cancer · 2022Article
- Inhibition of Proliferation in Ovarian Cancer Cell Line (PA-1) by the Action of Green Compound "Betanin".Applied biochemistry and biotechnology · 2022Article
- Nano-Based Drug Delivery and Targeting to Overcome Drug Resistance of Ovarian Cancers.Cancers · 2021Review
- Cancer of the ovary, fallopian tube, and peritoneum: 2021 update.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2021Review
- Calculating the dose of cisplatin that is actually utilized in hyperthermic intraperitoneal chemotherapy among ovarian cancer patients.Journal of ovarian research · 2021Article
- Crystal structures of chlorido-[dihy-droxybis-(1-imino-eth-oxy)]arsanido-κActa crystallographica. Section E, Crystallographic communications · 2020Article
- Comparison of aggregate and individual participant data approaches to meta-analysis of randomised trials: An observational study.PLoS medicine · 2020Observational
- Emerging serine-threonine kinase inhibitors for treating ovarian cancer.Expert opinion on emerging drugs · 2019Article
- Ovarian cancer: Current status and strategies for improving therapeutic outcomes.Cancer medicine · 2019Review
- Quality of Care and Outcomes of Patients With Gynecologic Malignancies Treated at Safety-Net Hospitals.JNCI cancer spectrum · 2019Article
- Chemotherapy Resistance in Advanced Ovarian Cancer Patients.Biomarkers in cancer · 2019Review
- Glutathione in Ovarian Cancer: A Double-Edged Sword.International journal of molecular sciences · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of this systematic study was to provide an up to date and reliable quantitative summary of the relative benefits of various types of chemotherapy (non-platinum vs platinum, single-agent vs combination and carboplatin vs cisplatin) in the treatment of advanced ovarian cancer. Also, to investigate whether well-defined patient subgroups benefit more or less from cisplatin- or carboplatin-based therapy. Meta-analyses were based on updated individual patient data from all available randomized controlled trials (published and unpublished), including 37 trials, 5667 patients and 4664 deaths. The results suggest that platinum-based chemotherapy is better than non-platinum therapy, show a trend in favour of platinum combinations over single-agent platinum, and suggest that cisplatin and carboplatin are equally effective. There is no good evidence that cisplatin is more or less effective than carboplatin in any particular subgroup of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.